Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Bortezomib (Primary) ; Iodine-131 tositumomab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 24 Mar 2010 Additional lead trial investigaotr (Kaminski M) added as reported by ClinicalTrials.gov record.
- 24 Mar 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.
- 12 Nov 2008 New trial record.